Combination therapies for traumatic brain injury: Retrospective considerations

Susan Margulies, Gail Anderson, Fahim Atif, Jerome Badaut, Robert Clark, Philip Empey, Maria Guseva, Michael Hoane, Jimmy Huh, Jim Pauly, Ramesh Raghupathi, Stephen Scheff, Donald Stein, Huiling Tang, Mona Hicks

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.

Original languageEnglish (US)
Pages (from-to)101-112
Number of pages12
JournalJournal of Neurotrauma
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Diffuse Axonal Injury
National Institutes of Health (U.S.)
Research
Edema
Therapeutics
Ischemia
Outcome Assessment (Health Care)
Clinical Trials
Hemorrhage
Inflammation
Wounds and Injuries
Traumatic Brain Injury
Behavior Rating Scale

Keywords

  • pharmacological interventions
  • preclinical therapeutic development
  • treatments

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Margulies, S., Anderson, G., Atif, F., Badaut, J., Clark, R., Empey, P., ... Hicks, M. (2016). Combination therapies for traumatic brain injury: Retrospective considerations. Journal of Neurotrauma, 33(1), 101-112. https://doi.org/10.1089/neu.2014.3855

Combination therapies for traumatic brain injury : Retrospective considerations. / Margulies, Susan; Anderson, Gail; Atif, Fahim; Badaut, Jerome; Clark, Robert; Empey, Philip; Guseva, Maria; Hoane, Michael; Huh, Jimmy; Pauly, Jim; Raghupathi, Ramesh; Scheff, Stephen; Stein, Donald; Tang, Huiling; Hicks, Mona.

In: Journal of Neurotrauma, Vol. 33, No. 1, 01.01.2016, p. 101-112.

Research output: Contribution to journalArticle

Margulies, S, Anderson, G, Atif, F, Badaut, J, Clark, R, Empey, P, Guseva, M, Hoane, M, Huh, J, Pauly, J, Raghupathi, R, Scheff, S, Stein, D, Tang, H & Hicks, M 2016, 'Combination therapies for traumatic brain injury: Retrospective considerations', Journal of Neurotrauma, vol. 33, no. 1, pp. 101-112. https://doi.org/10.1089/neu.2014.3855
Margulies S, Anderson G, Atif F, Badaut J, Clark R, Empey P et al. Combination therapies for traumatic brain injury: Retrospective considerations. Journal of Neurotrauma. 2016 Jan 1;33(1):101-112. https://doi.org/10.1089/neu.2014.3855
Margulies, Susan ; Anderson, Gail ; Atif, Fahim ; Badaut, Jerome ; Clark, Robert ; Empey, Philip ; Guseva, Maria ; Hoane, Michael ; Huh, Jimmy ; Pauly, Jim ; Raghupathi, Ramesh ; Scheff, Stephen ; Stein, Donald ; Tang, Huiling ; Hicks, Mona. / Combination therapies for traumatic brain injury : Retrospective considerations. In: Journal of Neurotrauma. 2016 ; Vol. 33, No. 1. pp. 101-112.
@article{7169dbe551e44a5f8f7cb851cb8d48c9,
title = "Combination therapies for traumatic brain injury: Retrospective considerations",
abstract = "Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.",
keywords = "pharmacological interventions, preclinical therapeutic development, treatments",
author = "Susan Margulies and Gail Anderson and Fahim Atif and Jerome Badaut and Robert Clark and Philip Empey and Maria Guseva and Michael Hoane and Jimmy Huh and Jim Pauly and Ramesh Raghupathi and Stephen Scheff and Donald Stein and Huiling Tang and Mona Hicks",
year = "2016",
month = "1",
day = "1",
doi = "10.1089/neu.2014.3855",
language = "English (US)",
volume = "33",
pages = "101--112",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapies for traumatic brain injury

T2 - Retrospective considerations

AU - Margulies, Susan

AU - Anderson, Gail

AU - Atif, Fahim

AU - Badaut, Jerome

AU - Clark, Robert

AU - Empey, Philip

AU - Guseva, Maria

AU - Hoane, Michael

AU - Huh, Jimmy

AU - Pauly, Jim

AU - Raghupathi, Ramesh

AU - Scheff, Stephen

AU - Stein, Donald

AU - Tang, Huiling

AU - Hicks, Mona

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.

AB - Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.

KW - pharmacological interventions

KW - preclinical therapeutic development

KW - treatments

UR - http://www.scopus.com/inward/record.url?scp=84952949019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952949019&partnerID=8YFLogxK

U2 - 10.1089/neu.2014.3855

DO - 10.1089/neu.2014.3855

M3 - Article

C2 - 25970337

AN - SCOPUS:84952949019

VL - 33

SP - 101

EP - 112

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 1

ER -